The FDA and state health regulators called for congressional action to bolster federal oversight of drug compounders as Congress prepared for hearings on a meningitis outbreak tied to the New England Compounding Center. "It is clear that the patchwork of disparate state regulations is not enough to keep the public safe," Massachusetts Department of Public Health interim Commissioner Dr. Lauren Smith wrote in prepared testimony filed with a House oversight panel. "FDA's authority over compounding pharmacies is more limited by law and needs to be strengthened," the FDA said. FDA Commissioner Dr. Margaret Hamburg is set to testify today.

Full Story:

Related Summaries